CLINICAL RESEARCH CENTER FOR OPIOID AND COCAINE ABUSE

该药物滥用研究中心包括一个核心和八个 主要项目分为三个药物开发部门： 1. 临床前神经生物学，2. 人体实验室研究和 3. 临床 试验。 核心激发了可卡因神经生物学的新方法 通过协调整个精神病学的研究工作来进行药物治疗， 药理学、核医学和检验医学。 它已经发展了 将创新研究理念纳入当前中心提案（例如安非他酮 飞行员、可卡因提示反应性、动物的位置偏好）以及 进入后来独立资助的项目（例如艾滋病毒痴呆症， 氟哌噻吨试点、美沙酮试点中的地昔帕明）。 核心资源有 还为学员的研究提供了技术和物质援助 导致独立资助研究的项目（例如 mazindol 飞行员，金刚烷胺飞行员）。 拟议的核心试点研究（例如 双硫仑用于酒精可卡因滥用者、焦虑症和可卡因） 应该延续这个传统。 八个主要项目中的三个是我们之前工作的延续： 1. 可卡因戒断的神经生物学，2. 可卡因戒断期间的挑战 维持药物疗法，3. 可卡因的代谢研究，重点是 可卡因与酒精的相互作用。 另一个原来的中心 项目已获得独立资助的赠款，例如当前的三个项目 丁丙诺啡研究，不再需要中心资助。 五新 项目由核心试点工作演变而来：1.动物模型筛选 药物并了解可卡因的分子机制 行动，2. SPECT 成像对多巴胺神经生物学的刺激作用 灵长类动物和人类，3. 可卡因线索反应性的人类实验室研究 在神经递质操纵和维护期间 药物治疗，4，5。安非他酮和安非他酮的临床试验 卡马西平。 增加了两个新的临床中心以增加 研究人员和研究对象库：West Haven V.A.和 康涅狄格大学。 因此，与我们当前中心的连续性 以及针对基础广泛的药物开发的重大新举措 计划已纳入我们的研究的继续 中心。

This center for Research on Substance Abuse includes a Core and eight major projects organized into three Divisions for medication development: 1. preclinical neurobiology, 2. human laboratory studies and 3. clinical trials. The Core has stimulated novel approaches to cocaine neurobiology and pharmacotherapy by coordinating research efforts across Psychiatry, Pharmacology, Nuclear Medicine and Laboratory Medicine. It has developed innovative research ideas into current Center proposals (e.g. buproprion pilot, cocaine cue reactivity, place preference in animals), as well as into projects that were later independently funded (e.g. HIV dementia, flupenthixol pilot, desipramine in methadone pilot). Core resources have also provided technical and material assistance in trainee' research projects that have led to independently funded research (e.g. mazindol pilot, amantadine pilot). Proposed pilot studies in the Core (e.g. disulfiram for alcoholic cocaine abusers, anxiety disorders and cocaine) should continue this tradition. Three of the eight major projects are continuations of our previous work: 1. the neurobiology of cocaine withdraw, 2. cocaine challenges during maintenance pharmacotherapies, 3. metabolic studies of cocaine focusing on the interaction of cocaine with alcohol. The other original Center projects have led to independently funded grants such as the three current buprenorphine studies, and no longer need Center funding. Five new projects evolved from Core pilot work: 1. animal models to screen medications and to understand the molecular mechanisms of cocaine's actions, 2. SPECT imaging of stimulant effects on dopamine neurobiology in primates and humans, 3. human laboratory studies of cocaine cue reactivity during neurotransmitter manipulation and during maintenance pharmacotherapy, and 4,5. clinical trials with buproprion and carbamazapine. Two new clinical sites have been added to increase the investigator and subject pools for studies: West Haven V.A. and the University of Connecticut. Thus, both continuity with our current Center and major new initiates towards a broad based medication development program have been incorporated into the continuation of our Research Center.